Branded Generics Market Size & Share 2023 to 2032
Market Size by Drug Class (Anti-hypertensive, Hormones, Antimetabolites), Application (Oncology, Cardiovascular Diseases), Route of Administration (Oral, Topical), Distribution Channel (Hospital Pharmacy), Global Forecast.
Report ID: GMI6565
|
Published Date: August 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Branded generics Market Size
Branded Generics Market size accounted for USD 238.4 billion in 2022 and is estimated to grow at 6.1% to reach USD 447.8 billion by 2032. The increasing number of patent expiry is set to provide a substantial boost to the market.
Branded Generics Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
For instance, some of the popular medications, including Humira from AbbVie, Januvia & Janumet from Merck, and Victoza from Novo Nordisk, among others, is expected to observe patent expiry in 2023. Therefore, such scenario creates a favourable landscape for generic drug manufacturers to step in. These branded generics offer equivalent therapeutic benefits as the original branded drugs at a lower cost. This cost-effectiveness serves as a major factor driving the demand for these alternatives.
Branded generics, also known as "branded off-patent generics" or "value-added generics," refer to pharmaceutical products that are off-patent but are marketed under a brand name by a company other than the one that originally developed by the drug. These products are essentially generic versions of previously patented drugs that have lost their exclusivity, allowing other manufacturers to produce and sell equivalent versions of the medication.
COVID-19 Impact
The emergence of the COVID-19 pandemic had a positive impact on branded generics market. As healthcare systems faced unprecedented challenges, the affordability and accessibility offered by branded generics became even more crucial. With economic pressures affecting individuals and healthcare budgets, the cost-effectiveness of branded generics emerged as a solution, allowing patients to access essential treatments without financial strain. Moreover, disruptions in global supply chains prompted a shift toward local manufacturing, and branded generics, often produced regionally, stepped in to ensure a stable supply of medications. Such factors have supplemented the market growth during pandemic. Moreover, the established safety profiles and simplified regulatory pathways of branded generics enable swift responses to urgent treatment needs.
Branded Generics Market Trends
The increasing prevalence of chronic diseases is expected to boost the market expansion. For instance, according to the Centers for Disease Control and Prevention (CDC) report, heart disease is the leading cause of death for men, and women in the U.S. In 2021, about 695,000 people in the U.S. died from heart disease. About 1 in 20 adults aged 20 and older have coronary artery disease. As chronic conditions become more widespread globally, the demand for long-term, affordable medications grows exponentially, thereby supplementing the market demand. Furthermore, chronic diseases often require consistent medication regimens to control symptoms and prevent exacerbations. Therefore, branded generics offer a viable solution, ensuring that patients can adhere to their prescribed therapies without compromise, thereby fostering the market share.
Branded Generics Market Restraint
The branded generics industry faces a significant challenge due to the competition posed by both standard generics and brand-name drugs. Standard generics, which are unbranded versions of medications, often have lower production costs due to simpler packaging and the absence of marketing expenses. This cost advantage can make them more appealing to both patients and healthcare providers seeking the most economical option. As a result, standard generics can divert market share away from branded generics, especially in price-sensitive markets. On the other hand, brand-name drugs, despite being more expensive, can carry a perception of higher quality and efficacy due to extensive marketing campaigns and the reputation of the original manufacturer. This perception can lead some patients and healthcare providers to favour brand-name drugs.
Branded Generics Market Analysis
By drug class, the branded generics market is classified into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics, and other drug classes. The anti-hypertensive segment accounted for 16.7% of the business share in 2022 and is projected to witness significant growth over the analysis timeframe. Increasing prevalence of hypertension is anticipated to accelerate the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC) report, in 2021, hypertension was a primary or contributing cause of 691,095 deaths in the U.S. This surge in cases translates into a heightened demand for effective and affordable treatments.
Based on application, the branded generics market is segmented into oncology, cardiovascular diseases, neurological diseases, gastrointestinal diseases, dermatological diseases, acute and chronic pain, and other applications. The oncology segment accounted for 29.8% of the revenue share in 2022. Rising abbreviated new drug application (ANDA) approvals and product launches will accelerate the market growth. For instance, there were 88 first-time generics approved in 2021 and 52 approvals through the Competitive Generic Therapy (CGT) route. Such increasing approvals will propel the market growth. Also, increasing cases of cancer across the globe is expected to boost the market growth. Therefore, demand of branded generics is expected to increase, thereby augmenting the segment growth.
Based on route of administration, the branded generics market is segmented into topical, oral, parenteral, and other routes of administration. The oral segment is projected to witness significant growth of 6.4% over the analysis timeframe. The widespread utilization of the oral route of administration for medication delivery serves as a prominent growth driver in the market. Also, advantages associated with oral medication such as ease of administration, enabling self-management and adherence to treatment regimens are anticipated to boost the market growth. Furthermore, Older individuals often prefer the convenience of oral medications due to factors such as ease of ingestion, familiarity, and the absence of invasive procedures. The act of swallowing a pill or tablet aligns with their established daily routines, fostering medication adherence and ensuring consistent therapeutic outcomes.
Based on distribution channel, the branded generics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment accounted for 49.8% of the business share in 2022 and is projected to witness lucrative growth over the analysis timeframe. Hospitals, as vital centers of healthcare delivery, demand a consistent supply of high-quality medications to treat diverse patient populations. The hospital pharmacies prioritize both patient care and budget constraints. Thus, the affordability of these medications allows hospitals to optimize resource allocation without compromising the quality of treatment, thereby supplementing market expansion. Furthermore, the growing inclination of patients towards choosing hospitals as their preferred treatment destinations is poised to significantly amplify market revenue.
North America branded generics market accounted for 40.8% revenue share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. A prominent growth driver for the market in North America is the region's robust healthcare infrastructure and the rising emphasis on cost-effective treatments. Also, rising product launches in the region will escalate the market growth. Such initiatives by market players are anticipated to drive the market growth. Moreover, surging government initiatives to promote generic products along with presence of key market in the region is expected to boost the market size.
Branded Generics Market Share
Major market players operating in the branded generics market include:
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
Branded Generics Industry News:
The branded generics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Drug Class
By Application
By Route of Administration
By Distribution Channel
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →